- Home
- DRIO vs BCAB Comparison
DRIO vs BCAB Comparison
Compare DRIO & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRIO
- BCAB
- Stock Information
- Founded
- DRIO 2011
- BCAB 2007
- Country
- DRIO United States
- BCAB United States
- Employees
- DRIO N/A
- BCAB N/A
- Industry
- DRIO Medical/Dental Instruments
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- DRIO Health Care
- BCAB Health Care
- Exchange
- DRIO Nasdaq
- BCAB Nasdaq
- Market Cap
- DRIO 27.9M
- BCAB 27.0M
- IPO Year
- DRIO N/A
- BCAB 2020
- Fundamental
- Price
- DRIO $0.59
- BCAB $0.35
- Analyst Decision
- DRIO Strong Buy
- BCAB Buy
- Analyst Count
- DRIO 1
- BCAB 2
- Target Price
- DRIO $2.00
- BCAB $1.00
- AVG Volume (30 Days)
- DRIO 293.8K
- BCAB 612.0K
- Earning Date
- DRIO 05-14-2025
- BCAB 03-27-2025
- Dividend Yield
- DRIO N/A
- BCAB N/A
- EPS Growth
- DRIO N/A
- BCAB N/A
- EPS
- DRIO N/A
- BCAB N/A
- Revenue
- DRIO $27,040,000.00
- BCAB $11,000,000.00
- Revenue This Year
- DRIO $22.40
- BCAB N/A
- Revenue Next Year
- DRIO $21.41
- BCAB N/A
- P/E Ratio
- DRIO N/A
- BCAB N/A
- Revenue Growth
- DRIO 32.86
- BCAB N/A
- 52 Week Low
- DRIO $0.56
- BCAB $0.24
- 52 Week High
- DRIO $1.93
- BCAB $4.02
- Technical
- Relative Strength Index (RSI)
- DRIO 38.41
- BCAB 42.04
- Support Level
- DRIO $0.62
- BCAB $0.28
- Resistance Level
- DRIO $0.74
- BCAB $0.40
- Average True Range (ATR)
- DRIO 0.05
- BCAB 0.04
- MACD
- DRIO -0.01
- BCAB 0.01
- Stochastic Oscillator
- DRIO 15.20
- BCAB 50.26
About DRIO DarioHealth Corp.
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and highly engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.